These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17184205)

  • 1. Overview of the pharmacoeconomics of pharmacogenetics.
    Dervieux T; Bala MV
    Pharmacogenomics; 2006 Dec; 7(8):1175-84. PubMed ID: 17184205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.
    Marra CA; Esdaile JM; Anis AH
    J Rheumatol; 2002 Dec; 29(12):2507-12. PubMed ID: 12465143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics and cost-effectiveness analysis: a two-way street.
    Chalkidou K; Rawlins M
    Drug Discov Today; 2011 Oct; 16(19-20):873-7. PubMed ID: 21903176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.
    Vegter S; Boersma C; Rozenbaum M; Wilffert B; Navis G; Postma MJ
    Pharmacoeconomics; 2008; 26(7):569-87. PubMed ID: 18563949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
    van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
    Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.
    Dervieux T; Meshkin B; Neri B
    Mutat Res; 2005 Jun; 573(1-2):180-94. PubMed ID: 15829247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
    Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
    Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of pharmacoeconomic studies of pharmacogenomic tests.
    Beaulieu M; de Denus S; Lachaine J
    Pharmacogenomics; 2010 Nov; 11(11):1573-90. PubMed ID: 21121811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genetic variations affect drug safety and efficacy].
    Harmsze AM; Deneer VH; Maitland-van der Zee AH; de Boer A; Klungel OH
    Ned Tijdschr Geneeskd; 2010; 154():A1503. PubMed ID: 20699026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics: implementing personalized medicine.
    Mini E; Nobili S
    Clin Cases Miner Bone Metab; 2009 Jan; 6(1):17-24. PubMed ID: 22461093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized drug therapy.
    Daly AK
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):29-36. PubMed ID: 17265738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis.
    Meckley LM; Veenstra DL
    Pharmacogenet Genomics; 2006 Feb; 16(2):139-47. PubMed ID: 16424826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical considerations for pharmacogenetic testing.
    Wedlund PJ
    MLO Med Lab Obs; 2001 Sep; 33(9):16-21, 23; quiz 24-5. PubMed ID: 11569125
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease.
    Roberts RL; Barclay ML
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1546-54. PubMed ID: 22741564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic testing for pharmacogenetics and its clinical application in drug therapy.
    Hiratsuka M; Sasaki T; Mizugaki M
    Clin Chim Acta; 2006 Jan; 363(1-2):177-86. PubMed ID: 16126184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.